News

UK scientists devise ‘one-hour test’ for TB


14 Sep 2010
by Working Group

This story originally appeared on BBC News. Click here to view.

By Neil Bowdler
Science reporter, BBC News

A coloured micrograph of a cross-section of the tuberculosis bacteria
A coloured micrograph of a cross-section of the tuberculosis bacteria

Scientists in the UK say they have devised a new ultra-sensitive test which can diagnose the presence of the tuberculosis bacterium in one hour.

The test has been developed by the Health Protection Agency (HPA).

Its developers claim the test can spot all strains of the disease and could reduce both the incidence and the consequences of the disease worldwide.

According to the World Health Organization, in 2008, an estimated 1.3 million people died from TB worldwide.

Genetic signature

The standard identification test for TB involves taking mucus coughed up from the lungs and growing a bacterial culture in the laboratory.

But it can take up to eight weeks to reach a diagnosis, by which time the individual might have infected many more people.

Other more rapid tests exist which scan for an antigen found in many TB strains, but they may not detect all infections, say the HPA.

The new test focuses on a particular DNA region within the bacterium which the researchers says is present in all strains of the disease.

Once a sample is taken, a scientific technique know as a “polymerase chain reaction” is used to amplify the volume of DNA available so that the genetic signature can be identified.

In the UK, around 9,000 cases of TB are reported each year, mainly in big cities like London
Source: World Health Organization/HPA

“This is a new test,” says the HPA’s Dr Cath Arnold, who led the study. “We’re looking for a genetic marker which is present in all strains of TB we’ve seen so far.”

We’re confident that it will pick up very small amounts and tests so far have show that it seems to be as sensitive as the gold standard of using culture, but there are various aspects which we need to develop further before we can offer it as an off-the-shelf product.”

Details of the work are being presented at the HPA’s annual conference at the University of Warwick.

The HPA test comes just weeks after details of a rival project were published in the New England Journal of Medicine.

The rival test is called “Xpert MTB/RIF” and its developers claim it can deliver a diagnosis in under two hours. They say their automated cartridge machine can also identify resistance to drugs used to treat TB.

Difficult diagnosis

Dr Mario Raviglione, director of the World Heath Organization’s Stop TB department, says these new generation tests could potentially revolutionise TB treatment.

“The diagnoses of TB is extremely difficult today. If you had a test which rapidly and at the point of care could detect TB immediately you would gain weeks or months in treating that person and avoid them going around for another five to eight weeks infecting others.”

The WHO estimates that a third of the world’s population carry TB bacteria. Only 5-10% of people who are infected become sick or infectious at some time during their life.

People with HIV and who carry TB bacteria are much more likely to develop the disease.

Recent years have seen a resurgence in TB infections in developed countries, and have seen the rise of strains resistant to medication.

Last year in the UK, the number of cases rose by more than 5% to 9,153, according to provisional figures from the HPA. More than a third of the cases were in London.

More News
19 Mar 2024
For World TB Day 2024, the WGND is spotlighting a monumental achievement in TB drug research and development: the Global TB Drug Pipeline has never been bigger than it is today. The number of drug candidates being clinically evaluated for use in the treatment of adult pulmonary TB has surpassed...
3 Aug 2023
The Working Group on New TB Drugs, in collaboration with the New Diagnostics Working Group, Working Group on New Vaccines, FIND, IAVI, and TB Alliance, is co-hosting a New Tools Summit at the Marriot Champs Elysée Hotel in Paris, France on Tuesday, 14 November 2023. The WGND Annual Meeting will be...
23 Aug 2022
The PAN-TB collaboration announced initial plans for a Phase 2 clinical trial evaluating two novel drug regimens to treat Tuberculosis. Sponsored by the Bill and Melinda Gates Foundation, the PAN-TB, or “Project to Accelerate New Treatments for Tuberculosis”, collaboration brings together non-...